Branddocs acquires and merges with TrustCloud – becomes the first global digital transactions choreographer
11.4.2023 12:30:00 EEST | Business Wire | Press release
Branddocs Inc, a prominent provider of secure digital transactions and video verification services, has announced today it is acquiring TrustCloud Inc, the world's first choreographing platform for secure digital transactions, in a move that strengthens its commitment to building trust and confidence in the digital economy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230411005217/en/
The Capabilities of the TrustCloud Choreography Platform (Graphic: Business Wire)
The newly merged company will trade as TrustCloud; combining former Branddocs’ large client base and its in-house network of fraud detection experts, AI/ML technologies, multi-orchestration capabilities and the widely acclaimed TrustCloud modular platform to deliver a globally compliant, frictionless and vendor-agnostic user journey. Clients include industry leaders such as JPMorgan Chase, Santander, BBVA, Willis Tower Watson, Direct Line and HDI, as well as government entities, healthcare providers and fast-growing Fintech companies, to name but a few.
“Knowing we can now offer one singular SaaS platform with one API and SLA across all our integrated vendors means our clients can now implement truly global and transformational orchestration solutions for every type of digital transaction – from eSignature to IAM and ID verification to the custody of digital assets in TrustCloud Vault. Our plug and play platform prevents the heartache of vendor lock-in, empowering clients with the freedom to choose any provider with per-transaction pricing. Any existing solution can be seamlessly integrated into TrustCloud’s vendor hub, which means zero interruption to our clients’ infrastructure and services,” states Branddocs’ CEO, Christoph Sauerwein.
As the world’s most certified Qualified Trust Service Provider (QTSP), TrustCloud effectively shields clients' global digital ecosystems, ensuring additional security and compliance at every level of transactional orchestration. Its unique choreographic ability allows for seamless management of high transaction volumes across various geographies while still maintaining an agile and adaptable approach.
“TrustCloud's unwavering commitment to building trust, coupled with cutting-edge technology and simplification of processes, enables businesses and consumers to engage in online transactions with greater ease and security. Due to our humanistic approach, by prioritising user control and visibility across the digital journey, we are seeing conversion rates significantly increase for our clients,” says Saioa Echebarria, CEO of TrustCloud.
About TrustCloud
TrustCloud is a secure digital transaction choreographer (SDTC) providing a range of services, including identity verification, authentication and authorization, encryption, digital signature verification, e-vaulting and e-archiving. These services are designed to protect the confidentiality, integrity, and availability of sensitive information, such as personal and financial data, throughout the entire digital transaction process. TrustCloud is also recognised as the most certified Qualified Trust Service Provider (QTSP) globally with certifications including ISO 27001, 17068, 22301, 27017, 27018, 27701, NIST 800-63 & 800-171, SOC2, HIPAA and eIDAS among others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005217/en/
Contact information
For further information visit Trustcloud.tech. For press enquiries email: press@trustcloud.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom